Supreme Court and Karnataka Highlight High Mark-Ups on Cancer Drugs, Seek Price Regulation
The Supreme Court of India criticized the large price differences between the cost of medicines supplied to retailers and their maximum retail prices (MRP), highlighting cases where cancer drugs are sold at up to ten times the supply price. Concurrently, Karnataka's government reported mark-ups on cancer drugs and medical devices ranging from 10 to over 52 times the procurement cost, urging the central government to regulate trade margins and improve pricing transparency. Petitions seek stricter enforcement of price controls under the Drugs (Prices Control) Order to prevent excessive profit margins in the drug supply chain.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is negative (32/100). Lens Score 67/100.
Outlets measured: indianexpress, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (28–35/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 1 Oct, 07:31 am. Other outlets followed.